Cover Image
市場調查報告書

皮黴菌病:開發中產品分析

Dermatomycoses - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 361628
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
皮黴菌病:開發中產品分析 Dermatomycoses - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 49 Pages
簡介

本報告提供皮黴菌病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

皮黴菌病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

皮黴菌病:企業開發中的治療藥

皮黴菌病:大學/機關研究中的治療藥

皮黴菌病:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

皮黴菌病:企業開發中的產品

皮黴菌病:大學/機關研究中的產品

皮黴菌病的治療藥開發企業

  • Anacor Pharmaceuticals, Inc.
  • Blueberry Therapeutics Ltd
  • Daewoong Pharmaceutical Co., Ltd.
  • Helix BioMedix, Inc.
  • TGV-Laboratories
  • Viamet Pharmaceuticals, Inc.

皮黴菌病:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

皮黴菌病:最近的開發平台趨勢

皮黴菌病:暫停中的計劃

皮黴菌病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8130IDB

Summary

Global Markets Direct's, 'Dermatomycoses - Pipeline Review, H1 2016', provides an overview of the Dermatomycoses pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dermatomycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dermatomycoses and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dermatomycoses
  • The report reviews pipeline therapeutics for Dermatomycoses by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Dermatomycoses therapeutics and enlists all their major and minor projects
  • The report assesses Dermatomycoses therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Dermatomycoses

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Dermatomycoses
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dermatomycoses pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dermatomycoses Overview
  • Therapeutics Development
    • Pipeline Products for Dermatomycoses - Overview
    • Pipeline Products for Dermatomycoses - Comparative Analysis
  • Dermatomycoses - Therapeutics under Development by Companies
  • Dermatomycoses - Therapeutics under Investigation by Universities/Institutes
  • Dermatomycoses - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Dermatomycoses - Products under Development by Companies
  • Dermatomycoses - Products under Investigation by Universities/Institutes
  • Dermatomycoses - Companies Involved in Therapeutics Development
    • Anacor Pharmaceuticals, Inc.
    • Blueberry Therapeutics Ltd
    • Daewoong Pharmaceutical Co., Ltd.
    • Helix BioMedix, Inc.
    • TGV-Laboratories
    • Viamet Pharmaceuticals, Inc.
  • Dermatomycoses - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AN-2718 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BB-2603 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dapaconazole - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DWP-06081 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HB-1275 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Myc-102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Fungal Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VT-1161 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Dermatomycoses - Recent Pipeline Updates
  • Dermatomycoses - Dormant Projects
  • Dermatomycoses - Product Development Milestones
    • Featured News & Press Releases
      • Jul 09, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Studies of VT-1161 with Moderate to Severe Interdigital Tinea Pedis
      • Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Dermatomycoses, H1 2016
  • Number of Products under Development for Dermatomycoses - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Dermatomycoses - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016
  • Dermatomycoses - Pipeline by Blueberry Therapeutics Ltd, H1 2016
  • Dermatomycoses - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016
  • Dermatomycoses - Pipeline by Helix BioMedix, Inc., H1 2016
  • Dermatomycoses - Pipeline by TGV-Laboratories, H1 2016
  • Dermatomycoses - Pipeline by Viamet Pharmaceuticals, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Dermatomycoses Therapeutics - Recent Pipeline Updates, H1 2016
  • Dermatomycoses - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Dermatomycoses, H1 2016
  • Number of Products under Development for Dermatomycoses - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top